Loading...
Combination of clinically utilized kappa opioid receptor agonist nalfurafine with low-dose naltrexone reduces excessive alcohol drinking in male and female mice
BACKGROUND: Nalfurafine is the first clinically approved kappa-opioid receptor (KOP-r) agonist as an anti-pruritus drug with few side effects in humans (e.g., sedation, depression and dysphoria). No study, however, has been done using nalfurafine on alcohol drinking in rodents or humans. METHODS: We...
Saved in:
| Published in: | Alcohol Clin Exp Res |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
2019
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6551307/ https://ncbi.nlm.nih.gov/pubmed/30908671 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/acer.14033 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|